Shanghai Longwood Biopharmaceuticals Co., Ltd.
Clinical trials sponsored by Shanghai Longwood Biopharmaceuticals Co., Ltd., explained in plain language.
-
New pill shows promise for arthritis sufferers
Disease control CompletedThis study tested a new tablet called LW402 in 72 adults with moderate to severe rheumatoid arthritis who were already taking methotrexate. The goal was to see if adding LW402 for 12 weeks could reduce joint pain and swelling better than a placebo. The trial is complete, and resu…
Phase: PHASE2 • Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
New eczema drug shows promise in Mid-Stage trial
Symptom relief CompletedThis study tested an experimental drug called LW402 in 144 adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if the drug reduces eczema severity, measured by a 50% improvement in skin symptoms after 12 weeks. Participants were randomly assigned to rec…
Phase: PHASE2 • Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. • Aim: Symptom relief
Last updated May 17, 2026 11:55 UTC
-
New drug LW402 passes early safety check in healthy volunteers
Knowledge-focused CompletedThis early-stage study tested the safety and tolerability of multiple doses of LW402 tablets in 36 healthy volunteers. Researchers monitored side effects and how the drug moves through the body. The goal was to gather safety information, not to treat any disease.
Phase: PHASE1 • Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. • Aim: Knowledge-focused
Last updated May 17, 2026 11:52 UTC